ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC

NEXT STORY
Adaptive Biotechnologies Announces Pricing of Initial Public Offering
PREV STORY
The 2019 U.S. HIV Market: Analyses & Forecasts Through 2014-2024
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

author_avatar
NASDAQ Market News

Philips and Mandaya Royal Hospital Puri sign seven-year partnership agreement to provide patient-centered care

author_avatar
NASDAQ Market News

World-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board

TEL AVIV, Israel, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), ...

author_avatar
NASDAQ Market News